Clinical Trials Logo

Filter by:
NCT ID: NCT01511276 Completed - Breast Cancer Risk Clinical Trials

The Effects of Equivalent Weight Loss With or Without Exercise Training on Breast Cancer Risk (SHAPE-2)

SHAPE-2
Start date: February 2012
Phase: N/A
Study type: Interventional

Physical inactivity and overweight are two accepted risk factors for breast cancer. However, because of their correlation it is not clear which is most relevant to risk. The investigators now set out to study whether physical activity in addition to weight loss by diet only, affects sex hormone levels, known to be related to breast cancer risk. In the SHAPE-2 study 250 healthy overweight/obese and physically inactive women are randomly allocated to a diet-induced weight loss group, a combined exercise- and diet-induced weight loss group or a control group. The aim of the first two intervention groups is to loose 5-6 kg of bodyweight, either by dieting or mainly by increased physical activity. Measurements are performed at baseline and after 21 weeks, the end of the study period. The aim of this study is to provide insight into the effect of weight loss mainly driven by exercise compared to equivalent weight loss due to nutritional calorie restriction on breast cancer biomarkers.

NCT ID: NCT01510652 Completed - Heart Failure Clinical Trials

More Options Available With a Quadripolar LV Lead pRovidE In-clinic Solutions to CRT Challenges

MORE-CRT
Start date: November 2011
Phase: N/A
Study type: Interventional

This investigation is designed with the hypothesis that using a quadripolar left ventricular lead results in less interventions when dealing with high pacing thresholds and Phrenic Nerve Stimulation (PNS), both at implant and during follow-up, compared to standard bipolar left ventricular leads.

NCT ID: NCT01510639 Completed - Clinical trials for Subacromial Impingement

The Influence of Growth Factors (PDGF), Applied as Autologous Thrombocyte Concentrate, on Functional Recovery

PRP
Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test the hypothesis that the application of PRP leads to faster wound healing, less wound healing disorders, less pain and faster functional recovery after subacromial surgery.

NCT ID: NCT01510288 Terminated - Prostate Cancer Clinical Trials

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Start date: November 2004
Phase: Phase 1
Study type: Interventional

Ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen 4, and GVAX have demonstrated anti-tumor activity in prostate cancer. Pre-clinical studies with this combination have demonstrated potent synergy. The purpose of this study is to investigate, using a phase-I 3+3 dose escalation design followed by an expansion cohort, the safety and efficacy of combined treatment with GVAX and ipilimumab in castration-resistant metastatic prostate cancer (CRPC) patients.

NCT ID: NCT01510210 Active, not recruiting - Atrial Fibrillation Clinical Trials

Risk Profile for Patients With Atrial Fibrillation

Start date: April 2011
Phase:
Study type: Observational

The objective of this study is to assess the risk profile in patients with atrial fibrillation, which represents the degree of changes in the atrial tissue and which can help predict in which patients rhythm control will be successful. This risk profile will consist of a combination of underlying (heart) disease and risk factors, measurements obtained from echocardiograms, and circulating biomarkers. Ultimately this risk profile can be used to guide type of rhythm control therapy in individual patients with atrial fibrillation.

NCT ID: NCT01510197 Completed - Atrial Fibrillation Clinical Trials

Risk Profile for Atrial Fibrillation

Start date: September 2011
Phase: N/A
Study type: Observational

The objective of this study is to assess the risk profile in patients with atrial fibrillation, which represents the degree of changes (remodeling) in the atrial tissue and which can help to predict in which patients rhythm control will be successful. This risk profile will consist of a combination of underlying (heart) disease and risk factors, as measured with use of parameters obtained with echocardiography, circulating biomarkers and other relevant clinical data. Ultimately this risk profile can be used to guide type of (rhythm) control therapy in individual patients with atrial fibrillation.

NCT ID: NCT01510184 Terminated - Clinical trials for Diffuse Large B-cell Lymphoma

Study of Zevalin Versus Observation in Participants at Least 60 Years Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in Positron Emission Tomography (PET)-Negative Complete Remission After Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) or R-CHOP-like Therapy

Start date: April 19, 2012
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Zevalin compared with observation alone in participants who are in PET-negative complete remission after first-line R-CHOP or R-CHOP like therapy.

NCT ID: NCT01509469 Completed - Obesity Clinical Trials

The Effect of Different Macronutrients on Ileal Brake Activation

Start date: March 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether ileal infusion of casein and sucrose can activate the ileal brake.

NCT ID: NCT01509222 Completed - Obesity Clinical Trials

Changing Dietary Patterns: an Individually Tailored Nutrition Intervention (OKE-study)

Start date: September 2011
Phase: N/A
Study type: Interventional

The main objective of this study is to investigate the effect of a personalized nutrition intervention on the dietary pattern of apparently healthy adults with one or more children aged 4 to 12 years.

NCT ID: NCT01508572 Completed - Breast Cancer Clinical Trials

VEGF-targeted Fluorescent Tracer Imaging in Breast Cancer

Start date: October 2011
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the uptake, (semi-)quantification and localization of the VEGF targeting fluorescent tracer bevacizumab-IDRye800CW in breast cancer tissue, surrounding healthy tissue, tumor margins and lymph nodes. This is measured in surgical specimens after a single intravenous administration of 4,5 bevacizumab-IDRye800CW, using fluorescence microscopy and macroscopy techniques. Also the safety of bevacizumab-IDRye800CW is assessed. Another purpose is to assess the abilities of three different fluorescent signal detection systems to detect the fluorescent signal pre- and intra-operatively.